Concert Pharma (CNCE) Misses Q3 EPS by 8c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.39), $0.08 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $4.5 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c